Expression System Advantages

The Company's proprietary expression technologies, including SEP^TM, are highly amenable to the development and commercial production of a broad array of biopharmaceuticals, including monoclonal antibodies, fusion proteins, and cytokines. More specifically, the SEP^TM enjoys the following characteristics and advantages:

• Peptide structure is 100% homologous to humans with glycans commonly found in human serum and cell membranes
  
  
• Significantly reduced cost of production: Capital investment required for facilities is 90% less than CHO systems and upstream manufacturing costs are 60-75% less than CHO
  
  
• Enhanced efficacy: SEP^TM naturally creates mAbs with 10 – 100 times the ADCC activity of mAbs produced in CHO systems
  
  
• Expression levels equivalent to or greater than CHO systems: Our expression levels are currently ~5 grams per liter and are set to double to ~10 grams per liter in 2009
  
  
• Comprehensive IP portfolio: 40 issued patents, over 80 pending applications covering products, vectors, promoters, and methods
  
  
• Commercial scalability without CHO system risks: No risk of structural deviations on scale-up and much less risk of batch to batch variability than CHO
  
  
• Production processes accepted by FDA and EMEA: Controlled, consistent, reliable production of safe and active glycosylated proteins